Q2 2025 marked a turning point for HealthTech as investor confidence returned and capital markets regained momentum. A more stable macro environment, falling inflation, and resilient public markets helped drive deal value across both M&A and private placements.
The AHT Index rose 8% YTD, outperforming the Nasdaq and S&P 500, with multiples expanding to 4.9x revenue. High-growth names in diagnostics, infrastructure, and care delivery software led the rally.
Notable transactions included Siemens’ $5bn acquisition of Dotmatics — the largest HealthTech deal YTD — as well as HealthEdge’s sale to BainCapital and Madison Dearborn’s buyout of NextGen. These transactions underscore a renewed focus on scaled digital platforms in payer and clinical infrastructure.
Private placement activity rebounded sharply, reaching $5.8bn, the highest aggregate value in 3 years. While deal count remained stable, larger rounds drove the jump in value, with transactions above $100mn. Transcarent’s $700mn and Cleerly’s $500mn raises stood out in a quarter dominated by high-conviction bets.
Investors showed continued preference for scalable, mission-critical platforms. Health Systems and Ambulatory Care led end-market activity, while Clinical Analytics attracted the largest share of private capital.
Macroeconomic indicators remained favorable, with U.S. GDP growing 4.1%, inflation easing to 2.9%, and unemployment stable at 3.9%. Public market sentiment improved in parallel, lifting growth-stage valuations and transaction appetite heading into H2.
Key Highlights in Q2:
- The AHT Index rose +8% YTD, led by OptimizeRx (+178%), Hims & Hers (+106%), and Tempus (+88%)
- Public company multiples expanded to 4.9x LTM revenue
- $5.8bn in private placements across 150 deals, with large rounds driving growth
- M&A volume totaled $15bn, led by Siemens / Dotmatics
- Health Systems remained the dominant end market; Clinical Analytics led sector capital allocation
